Market research
CTOR Citius Oncology, Inc.
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 97M
- P/E ratio
- Not available
- Analyst target
- 4
- Dividend yield
- Not available
- Beta
- 3.53
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- US17331Y1091
- Market cap
- 97M
- P/E ratio
- Not available
- Analyst target
- 4
- Dividend yield
- Not available
- Beta
- 3.53
About
About Citius Oncology, Inc.
Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Leonard-Meron Biosciences, Inc.
Visit company websiteCommunity
Investor discussion
0 comments
Sign in to join the CTOR discussion.
No comments yet
Start a focused discussion about CTOR.